JCP Summarizes Baumgardner Study on CAR-T Treatment Cost-Effectiveness
In the latest edition of the Journal of Clinical Pathways (JCP), Zachary Bessette summarizes PHE Senior Research Economist Jim Baumgardner’s recent ASH presentation, focused on studying the cost-effectiveness of novel CAR-T treatments. In the study, Dr. Baumgardner’s team asserts that the introduction of CAR-T therapies represents a major break from the trend of declining incremental effectiveness and provides similar cost-effectiveness to other innovations.
To read the summary in JCP, please click here.
In this unique one-hour webinar, Dr. Jena outlines a broader framework for assessing value to improve identification of not only the highest-value treatments, but also low-value therapies on which spending can safely be reduced.